Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04681001
Previous Study | Return to List | Next Study

Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04681001
Recruitment Status : Recruiting
First Posted : December 23, 2020
Last Update Posted : January 11, 2021
Sponsor:
Information provided by (Responsible Party):
Marinomed Biotech AG

Brief Summary:
This is a prospective, randomized placebo-controlled double blinded clinical trial in frontline healthcare workers managing COVID-19 patients. Participants will be weekly tested for SARS-CoV-2 and a panel of respiratory viruses. Treatment will be 3times a day for 84 days one puff into each nostirl and 3 puffs into mouth. Daily a symptom score will be recorded. The primary objective of the trial is to demonstrate that prophylactic treatment of health care workers managing COVID-19 patients with iota-carrageenan reduces symptoms of SARS-CoV-2 infections as well as infections with other respiratory viruses when compared to a placebo-treated control group.

Condition or disease Intervention/treatment Phase
Respiratory Viral Infection Common Cold Severe Acute Respiratory Syndrome (SARS) Pneumonia COVID-19 Corona Virus Disease Device: nasal spray Not Applicable

Detailed Description:

This is a prospective, randomized placebo-controlled double blinded clinical trial in frontline healthcare workers managing COVID-19 patients.

Screening - first day of treatment:

After signing the informed consent form eligible participants will be included. Immediately after inclusion and after first nasal swab, participants start with their first treatment.

In order to obtain nasal swabs and to assess adverse events the participants will visit the sites on a weekly basis over a period of 12 weeks.

3 times a day for 84 days (12 weeks):

  • 1 puff of Coldamaris pro. nasal spray into each nostril (1.2 mg/ml; 140 µl per puff) and
  • 3 puffs of Coldamaris pro. nasal spray into mouth Weekly sampling for testing of SARS-CoV-2 and respiratory virus panel (Influenza A, Human Metapneumovirus, Influenza A - subtype H1 Adenovirus, Influenza A - subtype H3 Parainfluenza 1, Influenza A - subtype 2009 H1N1, Parainfluenza 2, Influenza B Parainfluenza 3, SARS-CoV-2 Parainfluenza 4, Coronavirus HKU1 Respiratory Syncytial Virus A, Coronavirus N63L, Respiratory Syncytial Virus B, Coronavirus OC43, Rhinovirus/Enterovirus, Coronavirus 229E, Human Bocavirus) At begin and end of trial blood samples will be taken for differential blood count and for serology. The primary end point of the is the presence of COVID-19 symptoms including symptoms of respiratory viral infection. The primary hypothesis is a reduction of symptom days caused by SARS-CoV-2 and/or respiratory viral infection in health care workers treated with Coldamaris pro. nasal spray compared to placebo treated ones

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized placebo-controlled double blinded
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Clinical Trial to Evaluate the Efficacy of an Iota-Carrageenan Nasal Spray to Reduce Symptoms Caused by SARS-CoV-2 and Other Respiratory Viruses in Healthcare Workers Managing COVID-19 Patients
Actual Study Start Date : December 20, 2020
Estimated Primary Completion Date : May 30, 2021
Estimated Study Completion Date : June 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Coldamaris pro
One puff per nostril three puffs into mouth
Device: nasal spray
application of nasal spray into nostrils and mouth

Placebo Comparator: Coldamaris sine
One puff per nostril three puffs into mouth
Device: nasal spray
application of nasal spray into nostrils and mouth




Primary Outcome Measures :
  1. Presence of COVID-19 symptoms including symptoms of respiratory viral infection documented in a diary [ Time Frame: 84 days ]
    daily assessment of subjective COVID-19 symptom score


Secondary Outcome Measures :
  1. Nasal swabs for analysis of viruses by PCR [ Time Frame: 84 days ]
    weekly assessment of SARS-CoV-2, Influenza A, Human Metapneumovirus, Influenza A - subtype H1, Adenovirus, Influenza A - subtype H3, Parainfluenza 1, Influenza A - subtype 2009 H1N1, Parainfluenza 2, Influenza B, Parainfluenza 3, Parainfluenza 4, Coronavirus HKU1, Respiratory Syncytial Virus A, Coronavirus N63L, Respiratory Syncytial Virus B, Coronavirus OC43, Rhinovirus/Enterovirus, Coronavirus 229E, Human Bocavirus, Chlamydophila pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila

  2. Serology of antibodies against SARS-CoV-2 [ Time Frame: 84 days ]
    beginn and end of trial

  3. Number of viral co-infections dedected by PCR [ Time Frame: 84 days ]
    weekly nasal swabs for analysis of viruses



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age ≥18 years
  • Study participants that have given informed consent before any study related procedures are performed, and received a copy of signed consent form
  • Healthcare workers (nurses, doctors) employed and working at Gesundheitsverbund
  • Healthcare workers looking after confirmed COVID-19 positive patients in a secondary care setting such as Accident and Emergency departments, wards, operating theatres, outpatient departments, High Dependency Unit or Intensive Care Units

Exclusion Criteria:

  • The subject is related to any study personnel or has any other close ties or conflicts of interest with the study sponsor.
  • The subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study
  • Known hypersensitivity or allergy to any component of the test product
  • Severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease or a history or any current disease that is considered by the investigator as a reason for exclusion.
  • The subject has a clinically significant disease that could interfere with participation in the study, with the intervention being studied, or with the evaluation of symptoms. Specific exclusions include immune deficiency, autoimmune disease, substantive cardiovascular, endocrinological, neurological, respiratory, or gastrointestinal disease.
  • Asymptomatic disease such as elevated blood pressure or cholesterol will not be a reason for exclusion. Those with well-controlled mental illness (e.g. depression, anxiety) will be eligible. The enrolling physician will be empowered to exclude potential subjects that s/he deems unreliable.
  • Pregnant women at the time of recruitment will be excluded from the study
  • Current medication other than oral contraception, that is considered by the investigator as a reason for exclusion e.g. intranasal medication
  • Participation in another antiviral clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04681001


Contacts
Layout table for location contacts
Contact: Eva Prieschl-Grassauer, Dr. +43226290300 ext 220 eva.prieschl-grassauer@marinomed.com
Contact: Nicole Unger-Manhart, Dr. +43226290300 ext 138 nicole.unger-manhart@marinomed.com

Locations
Layout table for location information
Austria
Gesundheitsverbund, Klinik Favoriten Recruiting
Vienna, Austria, 1100
Contact: Iulia Niculescu, Dr.    +43160191 ext 72471    iulia.niculescu@gesundheitsverbund.at   
Gesundheitsverbund Klinik Floridsdorf Recruiting
Vienna, Austria, 1210
Contact: Aschang Valipour, MD    +43 127700992208    arschang.valipour@gesundheitsverbund.at   
Contact: Waltraud Huf, MD    +43 127700992208    waltraud.huf@gesundheitsverbund.at   
Sponsors and Collaborators
Marinomed Biotech AG
Investigators
Layout table for investigator information
Principal Investigator: Iulia Niculescu, MD Gesundheitsverbund; Klinik Favoriten;4. Medizinische Abteilung mit Infektions-und Tropenmedizin1100 Vienna
Layout table for additonal information
Responsible Party: Marinomed Biotech AG
ClinicalTrials.gov Identifier: NCT04681001    
Other Study ID Numbers: COVID-19/CHC_20_04
First Posted: December 23, 2020    Key Record Dates
Last Update Posted: January 11, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Marinomed Biotech AG:
Carragelose
Respiratory Virus
Iota-Carrageenan
Health CareWorker
Frontline Worker
Nasal Spray
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
COVID-19
Severe Acute Respiratory Syndrome
Virus Diseases
Common Cold
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Picornaviridae Infections